Reported Earnings • Jul 17
Second quarter 2026 earnings released: EPS: kr1.07 (vs kr0.82 in 2Q 2025) Second quarter 2026 results: EPS: kr1.07 (up from kr0.82 in 2Q 2025). Revenue: kr2.72b (up 5.5% from 2Q 2025). Net income: kr130.0m (up 30% from 2Q 2025). Profit margin: 4.8% (up from 3.9% in 2Q 2025). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. New Risk • Jun 18
New major risk - Revenue and earnings growth Earnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks High level of debt (62% net debt to equity). Large one-off items impacting financial results. Recent Insider Transactions • May 11
President & CEO recently bought kr780k worth of stock On the 8th of May, Fredrik Dalborg bought around 6k shares on-market at roughly kr142 per share. This transaction amounted to 9.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr2.3m worth in shares. Buy Or Sell Opportunity • Apr 30
Now 24% undervalued Over the last 90 days, the stock has risen 3.8% to kr143. The fair value is estimated to be kr188, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 16% in the next 2 years. Upcoming Dividend • Apr 30
Upcoming dividend of kr1.50 per share Eligible shareholders must have bought the stock before 07 May 2026. Payment date: 13 May 2026. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (0.9%). Reported Earnings • Apr 29
First quarter 2026 earnings released: EPS: kr1.04 (vs kr0.98 in 1Q 2025) First quarter 2026 results: EPS: kr1.04 (up from kr0.98 in 1Q 2025). Revenue: kr2.65b (down 2.1% from 1Q 2025). Net income: kr127.0m (up 6.7% from 1Q 2025). Profit margin: 4.8% (up from 4.4% in 1Q 2025). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • Apr 23
AddLife AB (publ) (OM:ALIF B) acquired CoaChrom Diagnostica GmbH. AddLife AB (publ) (OM:ALIF B) acquired CoaChrom Diagnostica GmbH on April 22, 2026. As part of the acquisition, CoaChrom will become part of AddLife’s Business Area Labtech. CoaChrom will continue to operate under its own brand and with a high degree of operational independence, in line with AddLife’s decentralized business model. The acquisition is expected to have a marginal positive impact on AddLife’s earnings per share during the current financial year.
For the period ending December 31, 2025, CoaChrom Diagnostica GmbH reported total revenue of approximately €10 million.
AddLife AB (publ) (OM:ALIF B) completed the acquisition of CoaChrom Diagnostica GmbH on April 22, 2026. Buy Or Sell Opportunity • Mar 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to kr139. The fair value is estimated to be kr176, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.6% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings are also forecast to grow by 9.1% per annum over the same time period. Buy Or Sell Opportunity • Feb 11
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 26% to kr138. The fair value is estimated to be kr177, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.6% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings are also forecast to grow by 9.1% per annum over the same time period. Announcement • Feb 09
AddLife AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026 AddLife AB (publ) announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 02, 2026 Declared Dividend • Feb 06
Dividend increased to kr1.50 Dividend of kr1.50 is 100% higher than last year. Ex-date: 7th May 2026 Payment date: 13th May 2026 Dividend yield will be 1.0%, which is higher than the industry average of 0.5%. Payout Ratios Payout ratio: 33%. Cash payout ratio: 16%. New Risk • Feb 05
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks High level of debt (63% net debt to equity). Large one-off items impacting financial results. Reported Earnings • Feb 05
Full year 2025 earnings released: EPS: kr4.60 (vs kr2.07 in FY 2024) Full year 2025 results: EPS: kr4.60 (up from kr2.07 in FY 2024). Revenue: kr10.4b (up 1.5% from FY 2024). Net income: kr560.0m (up 122% from FY 2024). Profit margin: 5.4% (up from 2.4% in FY 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year. Announcement • Feb 04
AddLife AB (publ) to Report Fiscal Year 2026 Results on Feb 03, 2027 AddLife AB (publ) announced that they will report fiscal year 2026 results on Feb 03, 2027 Reported Earnings • Oct 24
Third quarter 2025 earnings released: EPS: kr0.67 (vs kr0.20 in 3Q 2024) Third quarter 2025 results: EPS: kr0.67 (up from kr0.20 in 3Q 2024). Revenue: kr2.43b (up 3.6% from 3Q 2024). Net income: kr81.0m (up 238% from 3Q 2024). Profit margin: 3.3% (up from 1.0% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Announcement • Oct 23
AddLife AB (publ) to Report Q3, 2026 Results on Oct 21, 2026 AddLife AB (publ) announced that they will report Q3, 2026 results on Oct 21, 2026 Reported Earnings • Jul 16
Second quarter 2025 earnings released: EPS: kr0.82 (vs kr0.59 in 2Q 2024) Second quarter 2025 results: EPS: kr0.82 (up from kr0.59 in 2Q 2024). Revenue: kr2.58b (flat on 2Q 2024). Net income: kr100.0m (up 39% from 2Q 2024). Profit margin: 3.9% (up from 2.8% in 2Q 2024). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Recent Insider Transactions • Jun 07
President & CEO recently bought kr906k worth of stock On the 5th of June, Fredrik Dalborg bought around 5k shares on-market at roughly kr192 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr15m. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr2.0m worth in shares. Upcoming Dividend • May 02
Upcoming dividend of kr0.75 per share Eligible shareholders must have bought the stock before 09 May 2025. Payment date: 15 May 2025. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (0.7%). Reported Earnings • Apr 07
Full year 2024 earnings released: EPS: kr2.07 (vs kr1.56 in FY 2023) Full year 2024 results: EPS: kr2.07 (up from kr1.56 in FY 2023). Revenue: kr10.3b (up 6.2% from FY 2023). Net income: kr252.0m (up 33% from FY 2023). Profit margin: 2.4% (up from 2.0% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Announcement • Mar 27
AddLife AB (publ) Announces Håkan Roos Declines Re-Election to the Board AddLife AB (publ) announced that Håkan Roos has declined re-election to the board. Recent Insider Transactions • Mar 27
Independent Director recently bought kr15m worth of stock On the 21st of March, Håkan Roos bought around 100k shares on-market at roughly kr146 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr27m more in shares than they have sold in the last 12 months. Announcement • Mar 10
AddLife AB (publ) to Report Fiscal Year 2024 Final Results on Apr 04, 2025 AddLife AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 04, 2025 Buy Or Sell Opportunity • Feb 17
Now 20% undervalued Over the last 90 days, the stock has risen 37% to kr174. The fair value is estimated to be kr219, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has declined by 58%. For the next 3 years, revenue is forecast to grow by 6.8% per annum. Earnings are also forecast to grow by 30% per annum over the same time period. Declared Dividend • Feb 09
Dividend increased to kr0.75 Dividend of kr0.75 is 50% higher than last year. Ex-date: 9th May 2025 Payment date: 15th May 2025 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 36%. Cash payout ratio: 11%. Announcement • Feb 06
AddLife AB (publ), Annual General Meeting, May 08, 2025 AddLife AB (publ), Annual General Meeting, May 08, 2025, at 16:00 W. Europe Standard Time. Location: stockholm Sweden Reported Earnings • Feb 05
Full year 2024 earnings released: EPS: kr2.07 (vs kr1.56 in FY 2023) Full year 2024 results: EPS: kr2.07 (up from kr1.56 in FY 2023). Revenue: kr10.3b (up 6.2% from FY 2023). Net income: kr252.0m (up 33% from FY 2023). Profit margin: 2.4% (up from 2.0% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Dec 18
Independent Director recently bought kr9.9m worth of stock On the 13th of December, Håkan Roos bought around 70k shares on-market at roughly kr142 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr44m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Oct 27
President & CEO recently bought kr1m worth of stock On the 24th of October, Fredrik Dalborg bought around 7k shares on-market at roughly kr140 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr2.4m worth in shares. New Risk • Oct 24
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.2x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin). Reported Earnings • Oct 23
Third quarter 2024 earnings released: EPS: kr0.20 (vs kr0.20 in 3Q 2023) Third quarter 2024 results: EPS: kr0.20 (down from kr0.20 in 3Q 2023). Revenue: kr2.34b (up 1.1% from 3Q 2023). Net income: kr24.0m (down 4.0% from 3Q 2023). Profit margin: 1.0% (in line with 3Q 2023). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Reported Earnings • Jul 16
Second quarter 2024 earnings released: EPS: kr0.59 (vs kr0.26 in 2Q 2023) Second quarter 2024 results: EPS: kr0.59 (up from kr0.26 in 2Q 2023). Revenue: kr2.55b (up 8.0% from 2Q 2023). Net income: kr72.0m (up 125% from 2Q 2023). Profit margin: 2.8% (up from 1.4% in 2Q 2023). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Announcement • Jun 27
AddLife AB (publ) to Report Q1, 2025 Results on Apr 25, 2025 AddLife AB (publ) announced that they will report Q1, 2025 results at 7:45 AM, Central European Standard Time on Apr 25, 2025 Recent Insider Transactions • Jun 03
President & CEO recently bought kr856k worth of stock On the 27th of May, Fredrik Dalborg bought around 8k shares on-market at roughly kr114 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr32m. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr1.7m worth in shares. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Eva Elmstedt was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • May 17
Chief Financial Officer recently bought kr271k worth of stock On the 14th of May, Christina Rubenhag bought around 3k shares on-market at roughly kr108 per share. This transaction amounted to 63% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr32m. Christina has been a buyer over the last 12 months, purchasing a net total of kr465k worth in shares. Announcement • May 09
AddLife AB (publ) Approves Dividend, Payable on 16 May 2024 AddLife AB (publ) at its Annual General Meeting held on 8 May 2024 approved the dividend of SEK 0.50 per share, irrespectively of class of shares, was declared. Record date for the dividend was confirmed to be 13 May 2024. The dividend is expected to be remitted by Euroclear Sweden AB on 16 May 2024. Upcoming Dividend • May 03
Upcoming dividend of kr0.50 per share Eligible shareholders must have bought the stock before 10 May 2024. Payment date: 16 May 2024. Payout ratio is on the higher end at 78%, however this is supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of British dividend payers (5.9%). In line with average of industry peers (0.6%). Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: kr0.51 (vs kr1.43 in 1Q 2023) First quarter 2024 results: EPS: kr0.51 (down from kr1.43 in 1Q 2023). Revenue: kr2.57b (up 4.6% from 1Q 2023). Net income: kr62.0m (down 64% from 1Q 2023). Profit margin: 2.4% (down from 7.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Announcement • Apr 24
AddLife AB (publ) to Report Fiscal Year 2024 Results on Feb 05, 2025 AddLife AB (publ) announced that they will report fiscal year 2024 results on Feb 05, 2025 Recent Insider Transactions • Mar 22
Independent Director recently bought kr207k worth of stock On the 19th of March, Eva Elmstedt bought around 2k shares on-market at roughly kr104 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr32m. Insiders have collectively bought kr47m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 13
Independent Director recently bought kr32m worth of stock On the 7th of March, Håkan Roos bought around 315k shares on-market at roughly kr101 per share. This transaction amounted to 9.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr47m more in shares than they have sold in the last 12 months. Announcement • Mar 06
AddLife AB (publ) to Report Fiscal Year 2023 Results on Apr 05, 2024 AddLife AB (publ) announced that they will report fiscal year 2023 results at 9:00 AM, Central European Standard Time on Apr 05, 2024 Declared Dividend • Feb 11
Dividend of kr0.50 announced Shareholders will receive a dividend of kr0.50. Ex-date: 10th May 2024 Payment date: 16th May 2024 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 32%. Cash payout ratio: 13%. Recent Insider Transactions • Feb 07
President & CEO recently bought kr220k worth of stock On the 5th of February, Fredrik Dalborg bought around 2k shares on-market at roughly kr110 per share. This transaction amounted to 9.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr1.1m worth in shares. Reported Earnings • Feb 02
Full year 2023 earnings released: EPS: kr1.56 (vs kr3.94 in FY 2022) Full year 2023 results: EPS: kr1.56 (down from kr3.94 in FY 2022). Revenue: kr9.69b (up 6.6% from FY 2022). Net income: kr190.0m (down 60% from FY 2022). Profit margin: 2.0% (down from 5.3% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Dec 25
Independent Director recently bought kr521k worth of stock On the 21st of December, Håkan Roos bought around 8k shares on-market at roughly kr64.75 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr16m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to kr73.85, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 46% over the past three years. Recent Insider Transactions • Oct 29
Chief Financial Officer recently bought kr143k worth of stock On the 27th of October, Christina Rubenhag bought around 2k shares on-market at roughly kr63.50 per share. This transaction increased Christina's direct individual holding by 2x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr581k. This was Christina's only on-market trade for the last 12 months. Announcement • Oct 27
AddLife AB (publ) to Report First Half, 2024 Results on Jul 15, 2024 AddLife AB (publ) announced that they will report first half, 2024 results on Jul 15, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr2.32b (up 10% from 3Q 2022). Net income: kr25.0m (down 79% from 3Q 2022). Profit margin: 1.1% (down from 5.7% in 3Q 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Announcement • Oct 20
AddLife AB (publ), Annual General Meeting, May 08, 2024 AddLife AB (publ), Annual General Meeting, May 08, 2024, at 16:00 Central European Standard Time. Recent Insider Transactions • Oct 01
Independent Director recently bought kr581k worth of stock On the 25th of September, Håkan Roos bought around 9k shares on-market at roughly kr64.61 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr1.3m. Insiders have collectively bought kr47m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Sep 20
President & CEO recently bought kr208k worth of stock On the 18th of September, Fredrik Dalborg bought around 3k shares on-market at roughly kr69.33 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr1.3m. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr955k worth in shares. Recent Insider Transactions • Jul 27
Independent Chairman recently bought kr1.3m worth of stock On the 24th of July, Johan Sjo bought around 15k shares on-market at roughly kr84.00 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr12m. Johan has been a buyer over the last 12 months, purchasing a net total of kr5.6m worth in shares. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment deteriorates as stock falls 31% After last week's 31% share price decline to kr81.05, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 32x in the Life Sciences industry in Europe. Total loss to shareholders of 41% over the past three years. Reported Earnings • Jul 14
Second quarter 2023 earnings released: EPS: kr0.27 (vs kr0.61 in 2Q 2022) Second quarter 2023 results: EPS: kr0.27 (down from kr0.61 in 2Q 2022). Revenue: kr2.37b (up 14% from 2Q 2022). Net income: kr33.0m (down 55% from 2Q 2022). Profit margin: 1.4% (down from 3.6% in 2Q 2022). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Buying Opportunity • Jul 14
Now 22% undervalued Over the last 90 days, the stock is up 13%. The fair value is estimated to be kr144, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 19% in 2 years. Earnings is forecast to grow by 5.7% in the next 2 years. Recent Insider Transactions • May 28
Independent Director recently bought kr12m worth of stock On the 22nd of May, Håkan Roos bought around 87k shares on-market at roughly kr134 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr51m more in shares than they have sold in the last 12 months. Recent Insider Transactions • May 15
President & CEO recently bought kr129k worth of stock On the 12th of May, Fredrik Dalborg bought around 1k shares on-market at roughly kr129 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth kr139k. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr665k worth in shares. Announcement • May 06
Addlife AB (Publ) Declares Dividend Addlife AB (Publ) declared a dividend of SEK 1.20 per share, irrespectively of class of shares, was declared. Record date for the dividend was confirmed to be 8 May 2023. The dividend is expected to be remitted by Euroclear Sweden AB on 11 May 2023. Upcoming Dividend • Apr 28
Upcoming dividend of kr1.20 per share at 1.0% yield Eligible shareholders must have bought the stock before 05 May 2023. Payment date: 11 May 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (0.7%). Reported Earnings • Apr 27
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr2.46b (down 4.7% from 1Q 2022). Net income: kr174.0m (down 23% from 1Q 2022). Profit margin: 7.1% (down from 8.7% in 1Q 2022). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to kr110, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 32x in the Life Sciences industry in Europe. Total loss to shareholders of 52% over the past year. Simply Wall St's valuation model estimates the intrinsic value at kr102 per share. Recent Insider Transactions • Mar 28
President & CEO recently bought kr139k worth of stock On the 24th of March, Fredrik Dalborg bought around 2k shares on-market at roughly kr92.80 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr536k worth in shares. Recent Insider Transactions • Mar 09
President & CEO recently bought kr112k worth of stock On the 6th of March, Fredrik Dalborg bought around 1k shares on-market at roughly kr112 per share. This transaction amounted to 8.0% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth kr285k. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr397k worth in shares. Reported Earnings • Feb 04
Full year 2022 earnings released: EPS: kr3.94 (vs kr6.02 in FY 2021) Full year 2022 results: EPS: kr3.94 (down from kr6.02 in FY 2021). Revenue: kr9.08b (up 14% from FY 2021). Net income: kr480.0m (down 33% from FY 2021). Profit margin: 5.3% (down from 9.0% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Announcement • Feb 03
AddLife AB (publ) Proposes Dividend for the Year Ended December 31, 2022 The Board of directors of AddLife AB (publ) proposed a dividend of SEK 1.20 per share for the year ended December 31, 2022. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to kr130, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 34x in the Life Sciences industry in Europe. Total returns to shareholders of 84% over the past three years. Recent Insider Transactions • Dec 16
President & CEO recently bought kr285k worth of stock On the 14th of December, Fredrik Dalborg bought around 3k shares on-market at roughly kr114 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr30m. This was Fredrik's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 20% share price gain to kr123, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 35x in the Life Sciences industry in Europe. Total returns to shareholders of 129% over the past three years. Reported Earnings • Oct 27
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr2.10b (up 14% from 3Q 2021). Net income: kr120.0m (down 13% from 3Q 2021). Profit margin: 5.7% (down from 7.5% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
AddLife AB (publ) to Report Q1, 2023 Results on Apr 26, 2023 AddLife AB (publ) announced that they will report Q1, 2023 results at 7:45 AM, Central European Standard Time on Apr 26, 2023 Buying Opportunity • Aug 26
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 42%. The fair value is estimated to be kr177, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Earnings per share has grown by 51%. Revenue is forecast to grow by 1.9% in a year. Earnings is forecast to decline by 26% in the next year. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improved over the past week After last week's 17% share price gain to kr174, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 41x in the Life Sciences industry in Europe. Total returns to shareholders of 177% over the past three years. Reported Earnings • Jul 16
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr2.08b (down 8.7% from 2Q 2021). Net income: kr74.0m (down 58% from 2Q 2021). Profit margin: 3.6% (down from 7.8% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 1.3%, compared to a 25% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Jul 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 37%. The fair value is estimated to be kr203, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Earnings per share has grown by 59%. Revenue is forecast to decline by 1.5% in a year. Earnings is forecast to decline by 27% in the next year. Buying Opportunity • Jun 29
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 39%. The fair value is estimated to be kr200, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Earnings per share has grown by 59%. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment deteriorated over the past week After last week's 18% share price decline to kr183, the stock trades at a trailing P/E ratio of 30.7x. Average trailing P/E is 46x in the Life Sciences industry in Europe. Total returns to shareholders of 160% over the past three years. Recent Insider Transactions • Jun 06
CFO & Business Area Manager of Medtech recently sold kr8.5m worth of stock On the 30th of May, Martin Almgren sold around 35k shares on-market at roughly kr246 per share. This was the largest sale by an insider in the last 3 months. Martin has been a seller over the last 12 months, reducing personal holdings by kr8.6m. Valuation Update With 7 Day Price Move • May 19
Investor sentiment improved over the past week After last week's 18% share price gain to kr237, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 37x in the Life Sciences industry in Europe. Total returns to shareholders of 297% over the past three years. Upcoming Dividend • Apr 29
Upcoming dividend of kr2.00 per share Eligible shareholders must have bought the stock before 06 May 2022. Payment date: 12 May 2022. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of British dividend payers (4.6%). Higher than average of industry peers (0.6%). Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: kr6.02 (vs kr4.62 in FY 2020) Full year 2021 results: EPS: kr6.02 (up from kr4.62 in FY 2020). Revenue: kr7.99b (up 52% from FY 2020). Net income: kr718.6m (up 39% from FY 2020). Profit margin: 9.0% (in line with FY 2020). Over the next year, revenue is forecast to grow 9.4%, compared to a 11% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 65% per year whereas the company’s share price has increased by 68% per year. Recent Insider Transactions • Feb 08
President & CEO recently bought kr5.8m worth of stock On the 7th of February, Kristina Willgard bought around 30k shares on-market at roughly kr192 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Kristina has been a net seller over the last 12 months, reducing personal holdings by kr26m.